Literature DB >> 9003207

A cost of illness study of allergic rhinitis in the United States.

D C Malone1, K A Lawson, D H Smith, H M Arrighi, C Battista.   

Abstract

BACKGROUND: Allergic rhinitis is a common condition, but the burden of this condition on the national economy is not well understood.
OBJECTIVE: The purpose of this study was to estimate the national direct and indirect costs of allergic rhinitis.
METHODS: Data from the National Medical Expenditure Survey were used to provide estimates of resource utilization, medical expenditures, and lost productivity. With the complex survey design, variance estimates were used to construct confidence intervals for cost estimates of resource utilization and lost productivity.
RESULTS: It is estimated that approximately 39 million persons in the United States experienced allergic rhinitis in 1987. However, only 12.3% (4.8 million) sought medical treatment for allergic rhinitis. The total estimated cost of the condition, in 1994 dollars, was $1.23 billion (95% confidence interval, $846 million to $1.62 billion). Direct medical expenses accounted for 94% of total costs. Allergic rhinitis results in approximately 811,000 missed workdays, 824,000 missed school days, and 4,230,000 reduced activity days.
CONCLUSION: Allergic rhinitis clearly creates a burden in terms of the number of persons affected, total expenditures, and lost productivity. It also appears that a relatively large proportion of persons with allergic rhinitis were not seeking medical treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9003207     DOI: 10.1016/s0091-6749(97)70296-3

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  40 in total

Review 1.  Sedation, cognition, and antihistamines.

Authors:  Julie C Qidwai; Ginger S Watson; John M Weiler
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

Review 2.  Cost-of-illness studies. Useful for health policy?

Authors:  M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

3.  Variable expression of pathogenesis-related protein allergen in mountain cedar (Juniperus ashei) pollen.

Authors:  T Midoro-Horiuti; R M Goldblum; A Kurosky; T G Wood; E G Brooks
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

Review 4.  The economic burden of allergic rhinitis: a critical evaluation of the literature.

Authors:  Shelby D Reed; Todd A Lee; Douglas C McCrory
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 5.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 6.  Allergic rhinitis in children : diagnosis and management strategies.

Authors:  William E Berger
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults.

Authors:  Matteo Ruggeri; Marco Oradei; Franco Frati; Paola Puccinelli; Cristina Romao; Ilaria Dell'Albani; Cristoforo Incorvaia; Americo Cicchetti
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

8.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Epidemiology and burden of nasal congestion.

Authors:  Michael Stewart; Bj Ferguson; Len Fromer
Journal:  Int J Gen Med       Date:  2010-04-08

Review 10.  The link between allergic rhinitis and asthma: a role for antileukotrienes?

Authors:  H Kim; J Bouchard; P M Renzi
Journal:  Can Respir J       Date:  2008-03       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.